SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1899 participants.

Also called NCT05198674

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,899 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05198674
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Belgium, France, Germany, Greece, Ireland, Monaco, Netherlands, Sweden, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05198674. Allocation not applicable; no masking; primary purpose treatment. Start 2021-10-20 (actual); primary completion 2026-03-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Condition
Hypertension
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Condition
Chronic Kidney Diseases
Condition
Diabetes Mellitus
Intervention (Device)
Renal Denervation (Symplicity Spyral™)
Lead sponsor
Medtronic Vascular (class: industry)

Record details

Record id
cardio:ct-nct05198674
Content hash
e4da58c25b06d17ca20c9077810124d782678a9788c7be94189747138c910cc8